EXPRESSION LEVEL OF ESTROGEN RECEPTOR ß IN NON-SMALL CELL LUNG CANCER AND LUNG METASTSIS


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. A search for pathogenetically grounded approaches to the treatment of non-small cell lung cancer is undoubtedly one of the top priorities, because of the results of its treatment cannot be regarded as satisfactory. Discovery of a new type of receptors, estrogen receptors ß, that expressed in non-small cell lung cancer, created the preconditions for the development of a new treatment strategy for non-small cell lung cancer, namely antiestrogen therapy. Objective was to answer to the clinically significant question of how many patients with non-small cell lung cancer and lung metastases are potential candidates for antiestrogen treatment. Materials and methods. A comparative quantitative estimation of the level and frequency of the estrogen receptors ß expression in non-small cell lung cancer tissues and also in lung metastases (74 in total) was carried out by flow cytometry. Results. The estrogen receptors ß expression was detected in the majority of the investigated tumors and lung metastases, in 92 and 86 % of patients, respectively. The average level of estrogen receptors ß expression in non-small cell lung cancer tissue was higher then in metastases (42 % and 34.6 % respectively). The differences was statistically significant (p = 0.03). Primary tumors with a high and low+moderate estrogen receptors ß expression levels were detected in 35 % and 65 % of cases respectively and metastases with such expression levels - in 14 % and 86 % of cases respectively. Conclusion. 1. The estrogen receptors ß expression in the tumor predicts a more favorable course of the disease. One of the reasons for this may be a greater metastatic potential of tumor cells with low estrogen receptors ß expression. 2. The group of potential candidates for carrying out the adjuvant antiestrogen therapy comprises about 70 % of patients with primary lung tumors and with metastatic lesions of lung.

About the authors

B. E. Polotsky

ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» Минздрава России

Author for correspondence.
Russian Federation

B. B. Akhmedov

ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» Минздрава России

Russian Federation

E. A. Dudko

ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» Минздрава России

Russian Federation

E. A. Bogush

ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» Минздрава России

Email: labmedchem@mail.ru
Russian Federation

T. A. Bogush

ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» Минздрава России

Russian Federation

M. M. Davydov

ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» Минздрава России

Russian Federation

References

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c)


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС77-53039 от  04.03.2013.